Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
The net loss attributable to common shareholders for the fourth quarter of 2023 was $3.9 million, or $0.73 per basic and diluted share.
- The net loss attributable to common shareholders for the fourth quarter of 2023 was $3.9 million, or $0.73 per basic and diluted share.
- Revenues for the fourth quarter of 2023 were $7.0 million, compared to $2.6 million for the same period in 2022.
- Revenues for the fourth quarter of 2023 were comprised of revenues from collaborative research and development agreements with Bristol-Myers Squibb and grant revenue.
- For more details on MTEM’s financial results for 2023, refer to Form 10-K filed with the SEC.